Teva Reports New TEV-749 Olanzapine LAI Clinical Data
Tel Aviv, Israel, September18, 2026 Teva Pharmaceutical Industries Ltd. has announced new post hoc clinical data for TEV-‘749, its...
Teva Pharmaceutical Industries
Advertisement
Teva Reaches Investment Grade With S&P BBB- Upgrade
Tel Aviv, Israel, September 4, 2026 Teva Pharmaceutical Industries Ltd. has received an upgrade to BBB- from BB+ for...
Teva Reports Positive Phase 2a Results for TEV ‘408 in Celiac Disease
TEL AVIV, Israel, September 2, 2026 Teva Pharmaceutical Industries Ltd. has reported positive topline results from its ongoing Phase...
Teva Earns Investment-Grade Rating as Growth Strategy Advances
TEL AVIV, Israel, August 11, 2026 Teva Pharmaceutical Industries Ltd. announced that Moody’s Ratings has upgraded the company’s corporate...
Alvotech Announces FDA Acceptance of AVT16 Biosimilar Application for Entyvio
REYKJAVIK, Iceland, June 8, 2026 Alvotech announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
Advertisement
